Ki-67抗體 |
|
|
產(chǎn)品名稱 ： Ki-67抗體
產(chǎn)品類別 ： IVD診斷抗體原料
品 牌 ： GenomeMe
貨 號(hào) ： IHC067
規(guī) 格 ： 0.1ml/1ml
|
|
詳細(xì)信息 |
|
|
純化方式 ：
緩 沖 液 ：
應(yīng)用說明 ：
形 態(tài) ：
產(chǎn)品說明 ：
背景描述Description：
Ki-67是一種核內(nèi)非組蛋白，僅在細(xì)胞周期的活躍期(G1、S、G2和M期)表達(dá)，而在靜止期(G0和G1早期)不表達(dá)。雖然該抗原也與核糖體RNA轉(zhuǎn)錄相關(guān)，但它與細(xì)胞增殖密切相關(guān)，因此被認(rèn)為是對包括大腦、乳腺、宮頸和前列腺在內(nèi)的腫瘤的增殖率進(jìn)行分級(jí)的有效標(biāo)記物。
Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumors, including those of the brain, breast, cervix, and prostate.
Specifications：
Clone IHC067
Source Mouse Monoclonal
Positive Control Tonsil
Dilution Range 1:50-1:200
參考文獻(xiàn)References：
Mckeever P, et al. J Neuropathol Exp Neurol. 1998; 57:931-6.
Coons SW, et al. Neurosurgery. 1997; 41:878-84.
Allegra CJ, et al. J Clin Oncol. 2003; 21:241-50.
Pathmanathan N, et al. J Clin Pathol. 2013; 66:512-6.
Jansen R, et al. Br J Cancer. 1998; 78:460-65.
Goodson WH, et al. Breast Cancer Res Treat. 1998; 49:155-164.
Rossi S, et al. Am J Clin Pathol. 2005; 124:295-302.
Pena LL, et al. J Vet Diag Invest. 1998; 10:237-46.
Gibbons D, et al. Comparison Mod Pathol. 1997; 10:409-13.
|
|
| {返回} | |
| |||||||||||
